MusclePharm Corporation
MSLPQ
$0.00
$0.000.00%
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -18.44% | -22.34% | -17.38% | -17.51% | -20.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.44% | -22.34% | -17.38% | -17.51% | -20.48% |
| Cost of Revenue | 9.31% | -0.36% | -10.07% | -24.87% | -35.62% |
| Gross Profit | -82.74% | -72.61% | -38.21% | 13.37% | 74.80% |
| SG&A Expenses | -7.13% | -15.17% | -21.27% | -23.08% | -26.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.84% | -4.40% | -13.12% | -24.42% | -33.40% |
| Operating Income | -568.33% | -421.81% | -234.00% | 106.59% | 122.19% |
| Income Before Tax | -684.29% | -506.66% | -9.26% | 114.67% | 122.93% |
| Income Tax Expenses | 78.05% | 52.63% | -172.13% | -159.57% | -141.84% |
| Earnings from Continuing Operations | -676.85% | -503.96% | -5.69% | 115.15% | 123.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -676.85% | -503.96% | -5.69% | 115.15% | 123.06% |
| EBIT | -568.33% | -421.81% | -234.00% | 106.59% | 122.19% |
| EBITDA | -492.92% | -365.32% | -455.08% | 113.97% | 127.28% |
| EPS Basic | -667.23% | -495.64% | -1.89% | 110.60% | 113.29% |
| Normalized Basic EPS | -1,353.67% | -930.35% | -34.57% | 96.84% | 106.37% |
| EPS Diluted | -753.69% | -558.83% | 5.11% | 107.62% | 111.77% |
| Normalized Diluted EPS | -1,428.98% | -991.41% | -29.40% | 96.13% | 106.01% |
| Average Basic Shares Outstanding | 1.75% | 2.05% | 1.61% | 13.93% | 33.05% |
| Average Diluted Shares Outstanding | -16.31% | -0.69% | -1.10% | 38.40% | 61.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
